Metropolis Healthcare Ltd Stock Price Today (NSE: METROPOLIS)
Fundamental Score
Metropolis Healthcare Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Metropolis Healthcare Ltd share price today is ₹434.00, down 1.82% on NSE/BSE as of 30 March 2026. Metropolis Healthcare Ltd (METROPOLIS) is a Mid-cap company in the Healthcare Service Provider sector with a market capitalisation of ₹10.12K (Cr). The 52-week high for METROPOLIS share price is ₹2263.00 and the 52-week low is ₹421.20. At a P/E ratio of 63.98x, METROPOLIS is currently trading above its industry average P/E of 39.28x. The company has a Return on Equity (ROE) of 11.53% and a debt-to-equity ratio of 0.14.
Metropolis Healthcare Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Metropolis Healthcare Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Metropolis Healthcare Share Price: A Conservative Value Investor's Perspective
The healthcare service provider industry is facing increasing scrutiny on pricing and service quality, impacting profitability. This analysis examines the Metropolis Healthcare share price of ₹1986.90 (as of this writing) through the lens of a conservative value investor prioritizing capital safety. We observe that the company trades at a PE ratio of 63.98. This valuation merits a cautious approach. A high PE ratio could suggest the market has priced in future growth expectations which may not materialize.
A crucial metric for evaluating a company's efficiency is its Return on Capital Employed (ROCE). Metropolis Healthcare demonstrates a ROCE of 14.66%. This level of ROCE, while not insignificant, necessitates further investigation into its sustainability and competitive advantages. A higher ROCE, consistently maintained, suggests a stronger economic moat, implying that the company can generate superior returns on invested capital. Whether 14.66% builds a durable moat will depend on the ability to maintain and improve upon this performance in the future, relative to peers.
When considering investments, management quality becomes critical. Comparing Metropolis Healthcare Ltd to its peers, like
Suraksha Diagnostic Ltd, a value investor would assess their capital allocation decisions, historical performance through cycles, and overall transparency. Qualitative factors like management integrity and strategic vision play a major role in the long-term success of any enterprise. Further research should be undertaken to understand management's track record in driving organic growth and managing costs.Finally, it's important to remember that a single snapshot of a company's financials provides limited insight. This analysis forms part of a broader 80-parameter fundamental audit, verified by Sweta Mishra, which delves deeper into Metropolis Healthcare's financial health, competitive landscape, and long-term growth prospects. The goal is to identify potential risks and assess the margin of safety before making any investment decisions. It is important for investors to perform their own due diligence and consult with a qualified financial advisor before making any investment decisions.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Metropolis Healthcare Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of METROPOLIS across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Operating Margins (25.83%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (22.70%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.14)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (11.53x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹1034.52 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 45.62%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
3 factors identified
Premium Valuation Risk (P/E: 63.98x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (-1.02% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-0.56% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Metropolis Healthcare Ltd Financial Statements
Comprehensive financial data for Metropolis Healthcare Ltd including income statement, balance sheet and cash flow
About METROPOLIS (Metropolis Healthcare Ltd)
Metropolis Healthcare Ltd is a leading diagnostics company renowned for its comprehensive suite of services, extending from routine pathology tests to cutting-edge advanced diagnos...tics. With a legacy spanning decades, Metropolis has established itself as a trusted healthcare partner, committed to delivering accurate and reliable results that empower informed clinical decisions. Beyond standard blood tests and analyses, the company excels in specialised areas such as genetic testing, molecular diagnostics, and cytogenetic evaluations, catering to a wide spectrum of medical needs. Metropolis also prioritises preventive healthcare through tailored wellness packages and corporate screening programs, aimed at early detection and proactive health management. The breadth and depth of their offerings underscore Metropolis' dedication to holistic patient care and diagnostic excellence. Central to Metropolis' operational strength is its commitment to innovation and technological advancement. The company continuously invests in state-of-the-art laboratory equipment and employs rigorous quality control measures to ensure the highest standards of accuracy and efficiency. Furthermore, Metropolis offers convenient home collection services, bringing diagnostic care directly to patients' doorsteps, thereby enhancing accessibility and convenience. The organisation understands the importance of accurate and timely results so they contribute to improved patient outcomes. Metropolis also contributes to groundbreaking medical research by supporting clinical trials, leveraging its expertise in laboratory services. This focus on research not only advances scientific knowledge but also positions Metropolis at the forefront of diagnostic innovation. Metropolis Healthcare Ltd's influence extends beyond domestic borders, with a significant presence in international markets, including Africa, South Asia, and the Middle East. This global footprint reflects the company's commitment to providing quality diagnostic services to diverse populations and contributing to improved healthcare outcomes worldwide. Through its network of laboratories and collection centres, Metropolis delivers comprehensive diagnostic solutions to healthcare providers, hospitals, and individual patients. Moreover, the company's expertise in hospital lab management ensures efficient and effective laboratory operations within healthcare facilities, further enhancing the quality of patient care. By embracing innovation, maintaining uncompromising quality standards, and expanding its reach, Metropolis continues to shape the future of diagnostics and improve healthcare outcomes globally.
Company Details
Key Leadership
Corporate Events
Latest News
METROPOLIS Share Price: Frequently Asked Questions
What is the current share price of Metropolis Healthcare Ltd (METROPOLIS)?
As of 30 Mar 2026, 12:01 pm IST, Metropolis Healthcare Ltd share price is ₹434.00. The METROPOLIS stock has a market capitalisation of ₹10.12K (Cr) on NSE/BSE.
Is METROPOLIS share price Overvalued or Undervalued?
METROPOLIS share price is currently trading at a P/E ratio of 63.98x, compared to the industry average of 39.28x. Based on this relative valuation, the Metropolis Healthcare Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of METROPOLIS share price?
The 52-week high of METROPOLIS share price is ₹2263.00 and the 52-week low is ₹421.20. These values are updated daily from NSE/BSE price data.
What factors affect the Metropolis Healthcare Ltd share price?
Key factors influencing METROPOLIS share price include quarterly earnings growth (Sales Growth: 22.70%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Metropolis Healthcare Ltd a good stock for long-term investment?
Metropolis Healthcare Ltd shows a 5-year Profit Growth of -0.56% and an ROE of 11.53%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.14 before investing in METROPOLIS shares.
How does Metropolis Healthcare Ltd compare with its industry peers?
Metropolis Healthcare Ltd competes with major peers in the Healthcare Service Provider. Investors should compare METROPOLIS share price P/E of 63.98x and ROE of 11.53% against the industry averages to determine competitive standing.
What is the P/E ratio of METROPOLIS and what does it mean?
METROPOLIS share price has a P/E ratio of 63.98x compared to the industry average of 39.28x. Investors pay ₹64 for every ₹1 of annual earnings.
How is METROPOLIS performing according to Bull Run's analysis?
METROPOLIS has a Bull Run fundamental score of 48.9/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does METROPOLIS belong to?
METROPOLIS operates in the Healthcare Service Provider industry. This classification helps understand the competitive landscape and sector-specific trends affecting Metropolis Healthcare Ltd share price.
What is Return on Equity (ROE) and why is it important for METROPOLIS?
METROPOLIS has an ROE of 11.53%, which shows decent profitability but room for improvement. ROE measures how efficiently Metropolis Healthcare Ltd generates profits from shareholders capital.
How is METROPOLIS debt-to-equity ratio and what does it indicate?
METROPOLIS has a debt-to-equity ratio of 0.14, which indicates conservative financing with low financial risk.
What is METROPOLIS dividend yield and is it a good dividend stock?
METROPOLIS offers a dividend yield of 0.20%, meaning you receive ₹0.20 annual dividend for every ₹100 invested in Metropolis Healthcare Ltd shares.
How has METROPOLIS share price grown over the past 5 years?
METROPOLIS has achieved 5-year growth rates of: Sales Growth 9.22%, Profit Growth -0.56%, and EPS Growth -1.02%.
What is the promoter holding in METROPOLIS and why does it matter?
Promoters hold 48.89% of METROPOLIS shares, with 1.18% pledged. High promoter holding often indicates strong management confidence in Metropolis Healthcare Ltd.
What is METROPOLIS market capitalisation category?
METROPOLIS has a market capitalisation of ₹10124 crores, placing it in the Mid-cap category.
How volatile is METROPOLIS stock?
METROPOLIS has a beta of N/A. A beta > 1 suggests the Metropolis Healthcare Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is METROPOLIS operating profit margin trend?
METROPOLIS has a 5-year average Operating Profit Margin (OPM) of 25.83%, indicating the company's operational efficiency.
How is METROPOLIS quarterly performance?
Recent quarterly performance shows Metropolis Healthcare Ltd YoY Sales Growth of 22.70% and YoY Profit Growth of 13.22%.
What is the institutional holding pattern in METROPOLIS?
METROPOLIS has FII holding of 12.52% and DII holding of 33.10%. Significant institutional holding often suggests professional confidence in the Metropolis Healthcare Ltd stock.